JPH02138189A - Novel glycerin derivative, production thereof and drug composition containing same derivative - Google Patents
Novel glycerin derivative, production thereof and drug composition containing same derivativeInfo
- Publication number
- JPH02138189A JPH02138189A JP29147488A JP29147488A JPH02138189A JP H02138189 A JPH02138189 A JP H02138189A JP 29147488 A JP29147488 A JP 29147488A JP 29147488 A JP29147488 A JP 29147488A JP H02138189 A JPH02138189 A JP H02138189A
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- alkyl group
- carbon atoms
- branched alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002314 glycerols Chemical class 0.000 title claims description 22
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 239000000203 mixture Substances 0.000 title description 12
- 239000003814 drug Substances 0.000 title description 4
- 229940079593 drug Drugs 0.000 title description 4
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 47
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 13
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 125000003118 aryl group Chemical group 0.000 claims abstract description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 10
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 6
- 150000001450 anions Chemical class 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract description 45
- 229910019142 PO4 Inorganic materials 0.000 abstract description 26
- 239000010452 phosphate Substances 0.000 abstract description 26
- 208000010110 spontaneous platelet aggregation Diseases 0.000 abstract description 17
- 238000002360 preparation method Methods 0.000 abstract description 3
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- -1 ethylhexyl Chemical group 0.000 description 22
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical class OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- YTFJQDNGSQJFNA-UHFFFAOYSA-N benzyl dihydrogen phosphate Chemical compound OP(O)(=O)OCC1=CC=CC=C1 YTFJQDNGSQJFNA-UHFFFAOYSA-N 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- MRXXLYIVBJVALD-UHFFFAOYSA-N 1-phenylethyl dihydrogen phosphate Chemical compound OP(=O)(O)OC(C)C1=CC=CC=C1 MRXXLYIVBJVALD-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- BSCHIACBONPEOB-UHFFFAOYSA-N oxolane;hydrate Chemical compound O.C1CCOC1 BSCHIACBONPEOB-UHFFFAOYSA-N 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- YISWNDIWGWEDMI-UHFFFAOYSA-N (3-hydroxy-2-methoxypropyl) n-octadecylcarbamate Chemical compound CCCCCCCCCCCCCCCCCCNC(=O)OCC(CO)OC YISWNDIWGWEDMI-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000283977 Oryctolagus Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- MWPIIMNHWGOFBL-UHFFFAOYSA-N dichloromethane;toluene Chemical compound ClCCl.CC1=CC=CC=C1 MWPIIMNHWGOFBL-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000001196 nonadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Abstract
Description
【発明の詳細な説明】
[発明の産業上の利用分野]
本発明は、新規なグリセリン誘導体、その製造方法、お
よびそのグリセリン誘導体を含有する医薬組成物に関す
る。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application of the Invention] The present invention relates to a novel glycerin derivative, a method for producing the same, and a pharmaceutical composition containing the glycerin derivative.
[発明の背景]
近年において、血小板活性化因子[Platelet^
ctivating Factor、以下PAFと略す
コに関する研究が進められ、その種々の生理学的作用が
明らかになってきた。[Background of the invention] In recent years, platelet activating factor [Platelet^
Research on activating factor (hereinafter abbreviated as PAF) has been progressing, and its various physiological effects have become clear.
すなわちPAFは生体内機能として、アレルギ、炎症、
血小板凝集等に関与しており、そして一方では、強力な
血圧降下作用を有することが判明している。[ネイチャ
ー 285巻、193(I980) : Europe
an Journal of Pharmacolog
y。In other words, PAF has in-vivo functions such as allergies, inflammation,
It is involved in platelet aggregation, etc., and on the other hand, it has been found to have a strong blood pressure lowering effect. [Nature vol. 285, 193 (I980): Europe
a Journal of Pharmacolog
y.
65.185−192 (I980)]従って、PAF
の血小板凝集作用などの好ましくない作用を低減させる
こと、あるいは、血小板凝集を抑制することを目的とし
た研究が行なわれてきた。65.185-192 (I980)] Therefore, PAF
Research has been conducted with the aim of reducing undesirable effects such as platelet aggregation, or suppressing platelet aggregation.
PAFの血小板凝集を抑制するものとしては、グリセリ
ン誘導体が知られており、例えば、特開昭58−351
16号公報には、式
%式%
[式中、RIは炭素数10〜24のアルキル基を、R1
2は炭素数1〜4のアルキル基またはアラルキル基を、
Beは4級化された窒素を有する異項環基を示す]で表
わされるグリセリン誘導体またはその塩を含有する血小
板活性化因子抑制剤が開示されている。しかしながら、
このグリセリン誘導体の血小板凝集抑制作用は、必ずし
も充分であるとは言えない。Glycerin derivatives are known to suppress platelet aggregation in PAF, for example, as disclosed in Japanese Patent Application Laid-Open No. 58-351.
No. 16 describes the formula % formula % [where RI represents an alkyl group having 10 to 24 carbon atoms, R1
2 is an alkyl group or aralkyl group having 1 to 4 carbon atoms,
A platelet activating factor inhibitor containing a glycerin derivative or a salt thereof represented by the following formula: Be represents a quaternized nitrogen-containing heterocyclic group is disclosed. however,
The platelet aggregation inhibiting effect of this glycerin derivative cannot necessarily be said to be sufficient.
[発明の要旨]
本発明は、PAFの唾小板凝集作用に拮抗して優れた血
小板凝集抑制作用を示す新規なグリセリン誘導体、およ
びその製造方法を提供することを目的とする。[Summary of the Invention] An object of the present invention is to provide a novel glycerin derivative that exhibits an excellent platelet aggregation inhibitory effect by antagonizing the salivary platelet aggregation effect of PAF, and a method for producing the same.
また、本発明は、上記の新規なグリセリン誘導体を利用
した、優れた血小板凝集抑制作用を示す医薬組成物を提
供することも、その目的とする。Another object of the present invention is to provide a pharmaceutical composition that utilizes the above novel glycerin derivative and exhibits an excellent platelet aggregation inhibiting effect.
本発明の新規なグリセリン誘導体は、
一般式(■):
R’ CH−0−CONR2
古・
[式中、R1は、水素、または炭素数1〜4の直鎖もし
くは分枝鎖アルキル基を示し、R2は、炭素数10〜2
2の直鎖または分枝鎖アルキル基をボし、R3は、炭素
数1〜10の直鎖または分枝鎖アルキル基、置換基を有
してもよいアラルキル基(アルキレン基の炭素数は1〜
3)を示し、Qは、式(n)
(CH2)−CH−(CH2)。= (II)(但
し、R4は、炭素数1〜6のアルキル基、または低級ア
ルキル基で置換されていてもよいアリール基を示し、m
およびnは、それぞれ0〜2の整数であり、かつ、m+
n=0〜2を満足する数である)で表わされる基を示し
、Yは
5R6
−eN−(R5とR6とは、それぞれ独立に炭素数1〜
6の直鎖または分枝鎖アルキル基を示す)を環形成基と
して含む含窒素複素環基を示しくただし、含窒素複素環
基と隣接する基Qとは該環の炭素原子を介して結合して
いる)、そしてR7R8およびR9は、それぞれ独立に
水素、炭素数1〜6の直鎖または分枝鎖アルキル基、ア
リール基もしくはアラルキル基を示す]
で表わされるグリセリン誘導体である。The novel glycerin derivative of the present invention has the general formula (■): R' CH-0-CONR2 [wherein R1 represents hydrogen or a straight or branched alkyl group having 1 to 4 carbon atoms , R2 has 10 to 2 carbon atoms
2 is a straight-chain or branched-chain alkyl group, and R3 is a straight-chain or branched alkyl group having 1 to 10 carbon atoms, an aralkyl group that may have a substituent (the alkylene group has 1 carbon number, ~
3), Q is the formula (n) (CH2)-CH-(CH2). = (II) (However, R4 represents an alkyl group having 1 to 6 carbon atoms or an aryl group optionally substituted with a lower alkyl group, and m
and n are each an integer of 0 to 2, and m+
Y is a group represented by 5R6 -eN- (R5 and R6 are each independently a number satisfying 1 to 2 carbon atoms);
Indicates a nitrogen-containing heterocyclic group containing a straight-chain or branched alkyl group (6) as a ring-forming group, provided that the nitrogen-containing heterocyclic group and the adjacent group Q are bonded via a carbon atom of the ring. ), and R7R8 and R9 each independently represent hydrogen, a straight or branched alkyl group having 1 to 6 carbon atoms, an aryl group or an aralkyl group].
上記の本発明の新規なグリセリン誘導体は、一般式(■
):
RI
R’ CH−0−CONR2
R8C−0R3(■)
R9CH−0)(
[式中、RI R2、R3、R7R8およびR9は上
記と同一の意味を有する]
で表わされる化合物を、塩基の存在下に、オキシ塩化リ
ンおよび一般式(■):
HO−Q−Y−Aθ (TV)[式中、
AGIはアニオンを、Q、およびYは、上記と同一の意
味を有する]
で表わされる塩と反応させることを特徴とする、−数式
(I)二
R’ CH−0−CONH2
R9CH−0−P−0−Q−Y
e
[式中、R1、R2R3、R7R8R9QおよびYは、
上記と同じ意味を有する]で表わされるグリセリン誘導
体の製造方法により容易に製造することができる。The novel glycerin derivative of the present invention described above has the general formula (■
): RI R' CH-0-CONR2 R8C-0R3 (■) R9CH-0) ( [In the formula, RI R2, R3, R7R8 and R9 have the same meanings as above] In the presence of phosphorus oxychloride and general formula (■): HO-Q-Y-Aθ (TV) [wherein,
AGI is an anion, and Q and Y have the same meanings as above] - Formula (I) 2R' CH-0-CONH2 R9CH-0-P -0-Q-Y e [wherein R1, R2R3, R7R8R9Q and Y are
It can be easily produced by the method for producing a glycerin derivative represented by [having the same meaning as above].
[発明の効果]
本発明の新規なグリセリン誘導体は、優れたPAF拮抗
作用を示し、さらに具体的にはPAFの血小板凝集作用
に拮抗する優れた血小板凝集抑制作用を示す(例えば、
本発明の新規なグリセリン誘導体は、前記公知のグリセ
リン誘導体に比較して数倍強い作用を示す)。また、P
AFの作用としては、気管支収縮作用をも有することが
明かになっており、アレルギー反応や炎症反応の起因物
質の1つと考えられている。従って、PAFに拮抗する
本発明のグリセリン誘導体は、抗血小板剤として、血小
板凝集に関連する血栓症、脳出血、脳血栓、心筋梗塞、
狭心症、血栓性静脈炎、糸球体腎炎、およびエンドトキ
シンショック等のショックの予防、治療に有用である。[Effect of the Invention] The novel glycerin derivative of the present invention exhibits an excellent PAF antagonizing effect, and more specifically exhibits an excellent platelet aggregation inhibiting effect that antagonizes the platelet aggregation effect of PAF (for example,
The novel glycerin derivative of the present invention exhibits several times stronger action than the above-mentioned known glycerin derivatives). Also, P
It has been revealed that AF also has a bronchoconstrictive effect, and is considered to be one of the causative agents of allergic reactions and inflammatory reactions. Therefore, the glycerin derivative of the present invention that antagonizes PAF can be used as an antiplatelet agent to treat thrombosis related to platelet aggregation, cerebral hemorrhage, cerebral thrombosis, myocardial infarction,
It is useful for the prevention and treatment of shocks such as angina pectoris, thrombophlebitis, glomerulonephritis, and endotoxic shock.
それ以外にも、抗ぜん息剤、抗アレルギー剤郭よび抗炎
症剤としても有用である。またそれ以外にも抗腫瘍作用
を示す。In addition, it is useful as an anti-asthmatic agent, an anti-allergy agent, and an anti-inflammatory agent. It also exhibits other antitumor effects.
[発明の詳細な記述]
一般式(I)において、R1は、水素原子、または、メ
チル、エチル、プロピル、i−プロピル、ブチル、t−
ブチルのような炭素数1〜4の直鎖もしくは分枝鎖アル
キル基を示す。[Detailed description of the invention] In general formula (I), R1 is a hydrogen atom, or methyl, ethyl, propyl, i-propyl, butyl, t-
Represents a straight or branched alkyl group having 1 to 4 carbon atoms, such as butyl.
数式(I)において、R2は、デシル、ウンデシル、ド
デシル、トリデシル、テトラデシル、ペンタデシル、ヘ
キサデシル、ヘプタデシル、オクタデシル、ノナデシル
、アイコシル、ヘナイコシル、トコシルのような炭素数
10〜22の直鎖または分枝鎖アルキル基を示す。R2
は、特に、炭素数12〜20の直鎖または分枝鎖アルキ
ル基であることが好ましい。In formula (I), R2 is a straight or branched alkyl having 10 to 22 carbon atoms such as decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl, eicosyl, henaicosyl, tocosyl. Indicates the group. R2
is preferably a linear or branched alkyl group having 12 to 20 carbon atoms.
R3は、メチル、エチル、プロピル、イソプロピル、ブ
チル、ペンチル、ヘキシル、ヘプチル、オクチル、2−
エチルヘキシル、ノニル、デシルなどの炭素数1〜10
の直鎖または分枝鎖アルキル基、置換基を有してもよい
ベンジル、フェニルエチルなどのアラルキル基(アルキ
レン基の炭素数は1〜3)を示す。R3 is methyl, ethyl, propyl, isopropyl, butyl, pentyl, hexyl, heptyl, octyl, 2-
1 to 10 carbon atoms such as ethylhexyl, nonyl, decyl, etc.
represents a linear or branched alkyl group, an aralkyl group such as benzyl or phenylethyl which may have a substituent (the alkylene group has 1 to 3 carbon atoms).
Qは、式(II)
− (CH2)−−CH(CH2)。−(n)(但し
、R4は、炭素数1〜6のアルキル基、または低級アル
キル基で置換されていてもよいアリール基を示し、フェ
ニル、トリル、エチルフェニルなとであることが好まし
く、mおよびnは、それぞれO〜2の整数であり、かつ
、m+n=0〜2を満足する数であり、mおよびnは、
それぞれ0であることが好ましい)で表わされる基を示
す。Q is formula (II) - (CH2)--CH(CH2). -(n) (However, R4 represents an alkyl group having 1 to 6 carbon atoms or an aryl group optionally substituted with a lower alkyl group, and is preferably phenyl, tolyl, ethylphenyl, m and n are each an integer from 0 to 2, and a number satisfying m+n=0 to 2, and m and n are
each is preferably 0).
立に、炭素数1〜6の直鎖または分枝鎖アルキル基を示
し、メチル、エチル、プロピル、ブチルであることが好
ましい)を環形成基として含む含窒素複素環基を示す。It refers to a nitrogen-containing heterocyclic group containing a straight or branched alkyl group having 1 to 6 carbon atoms (preferably methyl, ethyl, propyl, or butyl) as a ring-forming group.
そして、Yは、その含窒素複素環を構成する炭素原子、
好ましくは窒素原子に隣接する炭素原子を介してQに結
合している。And, Y is a carbon atom constituting the nitrogen-containing heterocycle,
Preferably, it is bonded to Q via a carbon atom adjacent to the nitrogen atom.
このような含窒素複素環基の例を以下に示す。Examples of such nitrogen-containing heterocyclic groups are shown below.
ただし、以下の例は、置換基R5R6等の存在を別に考
えた含窒素複素環基骨格の例である。However, the following examples are examples of nitrogen-containing heterocyclic group skeletons in which the presence of substituents R5R6 and the like is taken into account.
2−ピロリジニル、3−ピロリジニル、2−ピペリジニ
ル、3−ピペリジニル、4−ピペリジニル、2−パーヒ
ドロアゼピニル、3−パーヒドロアゼピニル等の各基の
四級塩
R7RaおよびR9は、それぞれ独立に、水素、メチル
、エチル、n−プロピル、イソブロピル、n−ブチル、
イソブチル、ペンチル、ヘキシルなどの炭素数1〜6の
直鎖または分枝鎖アルキル基、フェニル、トリルおよび
キシリルのような置換フェニルなどのアリール基、もし
くはベンジル、フェニルエチルなどのアラルキル基を示
す。Quaternary salts of each group such as 2-pyrrolidinyl, 3-pyrrolidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-perhydroazepinyl, 3-perhydroazepinyl, etc. R7Ra and R9 are each independently , hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl,
It represents a linear or branched alkyl group having 1 to 6 carbon atoms such as isobutyl, pentyl, hexyl, an aryl group such as substituted phenyl such as phenyl, tolyl and xylyl, or an aralkyl group such as benzyl or phenylethyl.
R7、R11およびR9が、すべて水素であるか、ある
いはR7が、炭素数1〜6の直鎖または分枝鎖アルキル
基であり、R8とR9が共に水素であるか、あるいはR
9が、炭素数1〜6の直鎖または分枝鎖アルキル基であ
り、R7とR8が共に水素であることが特に好ましい。R7, R11 and R9 are all hydrogen, or R7 is a straight or branched alkyl group having 1 to 6 carbon atoms, and R8 and R9 are both hydrogen, or R
It is particularly preferred that 9 is a straight or branched alkyl group having 1 to 6 carbon atoms, and that R7 and R8 are both hydrogen.
次に本発明の化合物の具体例を挙げる。Next, specific examples of the compounds of the present invention will be given.
(I)3−ヘキサデシルカルバモイルオキシ2−メトキ
シプロピル・erythro −1、1−ジメチルピロ
リジニオ−2−イルフェニルメチル・ホスフェート
(2)3−ヘプタデシルカルバモイルオキシ=2−メト
キシプロピル−erythro −1、1−ジメチルピ
ロリジニオ−2−イルフェニルメチル・ホスフェート
(3)2−メトキシ−3−オクタデシルカルバモイルオ
キシプロピル・erythro −1、1−ジメチルピ
ロリジニオ−2−イルフェニルメチル・ホスフェート
(4)2−エトキシ−3−オクタデシルカルバモイルオ
キシプロピル・eryLhro −1、1−ジメチルピ
ロリジニオ−2−イルフェニルメチル・ホスフェート
(5)2−メトキシ−3−オクタデシルカルバモイルオ
キシプロピル・threo −1、1−ジメチルピロリ
ジニオ−2−イルフェニルメチル・ホスフェート
(6)2−メトキシ−3−オクタデシルカルバモイルオ
キシプロピル・erythro −1、1−ジエチルピ
ロリジニオ−2−イルフェニルメチル・ホスフェート
(7)2−メトキシ−3−オクタデシルカルバモイルオ
キシプロピル・erythro −1、1−ジメチルピ
ペリジニオ−2−イルフェニルメチル・ホスフェート
(8)2−メトキシ−3−オクタデシルカルバモイルオ
キシプロピル・2−(I,1−ジメチルピロリジニオ−
2−イル)−1−フェニルエチル・ホスフェート
(9)3− (N−ヘキサデシル−N−メチル)カルバ
モイルオキシ−2−メトキシプロピル・erythro
−1、1−ジメチルピロリジニオ−2−イルフェニル
メチル・ホスフェート
(I0)3−(N−エチル−N−ヘキサデシル)カルバ
モイルオキシ−2−メトキシプロピル・erythro
−1、1−ジメチルピロリジニオ−2イルフエニルメ
チル・ホスフェート
(I1) 3− (N−ヘプタデシル−N−メチル)カ
ルバモイルオキシ−2−メトキシプロピル・eryth
ro −1、1−ジメチルピロリジニオ−2=イルフエ
ニルメチル・ホスフェート
(I2) 2−メトキシ−3−くN−メチル−N−オク
タデシル)カルバモイルオキシプロピル・eryLhr
o −1、1−ジメチルピロリジニオ−2−イルフェニ
ルメチル・ホスフェート
(+3)3−(N−エチル−N−オクタデシル)カルバ
モイルオキシ−2−メトキシプロピル・eryt、hr
o −1、1−ジメチルピロリジニオ−2イルフエニル
メチル・ホスフェート
(I4) 2−エトキシ−3−(N−メチル−N−オク
タデシル)カルバモイルオキシプロピル・erythr
o −1、1−ジメチルピロリジニオ−2−イルフェニ
ルメチル・ホスフェート
(I5) 2−エトキシ−3−(N−エチル−N−オク
タデシル)カルバモイルオキシプロピル・erythr
o −1、1−ジメチルピロリジニオ−2−イルフェニ
ルメチル・ホスフェート
(IB) 2−メトキシ−3−(N−メチル−N−オク
タデシル)カルバモイルオキシプロピル・threo
−1、1−ジメチルピロリジニオ−2−イルフェニルメ
チル・ホスフェート
(I7) 2−メトキシ−3−(N−メチル−N−オク
タデシル)カルバモイルオキシプロピル・erythr
o −1、1−ジメチルピペリジニオ−2−イルフェニ
ルメチル・ホスフェート
(I8) 2−メトキシ−3−(N−メチル−N−オク
タデシル)カルバモイルオキシプロピル・erythr
o −1、1−ジエチルピロリジニオ−2−イルフェニ
ルメチル・ホスフェート
(I9) 2−メトキシ−3−(N−メチル−N−オク
タデシル)カルバモイルオキシプロピル・2−(t、i
−ジメチルピロリジニオ−2−イル)1−フェニルエチ
ル・ホスフェート
(20) 3−ヘキサデシルカルバモイルオキシ−2−
メトキシブチル−erythro −1、1−ジメチル
ピロリジニオ−2−イルフェニルメチル・ホスフェート
(21) 3−ヘプタデシルカルバモイルオキシ−2−
メトキシ−1−メチルプロピル・erythro −1
,1−ジメチルピペリジニオ−2−イルフェニルメチル
・ホスフェート
(22) 3−オクタデシルカルバモイルオキシ2−メ
トキシ−2−メチルプロピル・erythro −1,
1−ジメチルピロリジニオ−2−イルフェニルメチル・
ホスフェート
なお、本発明の一般式(I)で示される化合物は、不斉
炭素によって生じる各々の異性体及びそれらの混合物も
含むものである。(I) 3-hexadecylcarbamoyloxy 2-methoxypropyl erythro -1, 1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (2) 3-heptadecylcarbamoyloxy 2-methoxypropyl erythro -1 , 1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (3) 2-methoxy-3-octadecylcarbamoyloxypropyl erythro-1, 1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (4) 2-ethoxy-3-octadecylcarbamoyloxypropyl・eryLhro-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (5) 2-methoxy-3-octadecylcarbamoyloxypropyl・threo-1,1-dimethyl Pyrrolidinio-2-ylphenylmethyl phosphate (6) 2-methoxy-3-octadecylcarbamoyloxypropyl erythro-1,1-diethylpyrrolidinio-2-ylphenylmethyl phosphate (7) 2-methoxy- 3-octadecylcarbamoyloxypropyl erythro-1,1-dimethylpiperidinio-2-ylphenylmethyl phosphate (8) 2-methoxy-3-octadecylcarbamoyloxypropyl 2-(I,1-dimethylpyrrolidinio) −
2-yl)-1-phenylethyl phosphate (9) 3-(N-hexadecyl-N-methyl)carbamoyloxy-2-methoxypropyl erythro
-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (I0) 3-(N-ethyl-N-hexadecyl)carbamoyloxy-2-methoxypropyl erythro
-1,1-dimethylpyrrolidinio-2yl phenylmethyl phosphate (I1) 3-(N-heptadecyl-N-methyl)carbamoyloxy-2-methoxypropyl eryth
ro -1,1-dimethylpyrrolidinio-2=ylphenylmethyl phosphate (I2) 2-methoxy-3-(N-methyl-N-octadecyl)carbamoyloxypropyl eryLhr
o -1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (+3) 3-(N-ethyl-N-octadecyl)carbamoyloxy-2-methoxypropyl eryt, hr
o -1,1-dimethylpyrrolidinio-2yl phenylmethyl phosphate (I4) 2-ethoxy-3-(N-methyl-N-octadecyl)carbamoyloxypropyl erythr
o -1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (I5) 2-ethoxy-3-(N-ethyl-N-octadecyl)carbamoyloxypropyl erythr
o -1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (IB) 2-methoxy-3-(N-methyl-N-octadecyl)carbamoyloxypropyl threo
-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (I7) 2-methoxy-3-(N-methyl-N-octadecyl)carbamoyloxypropyl erythr
o -1,1-dimethylpiperidinio-2-ylphenylmethyl phosphate (I8) 2-methoxy-3-(N-methyl-N-octadecyl)carbamoyloxypropyl erythr
o -1,1-diethylpyrrolidinio-2-ylphenylmethyl phosphate (I9) 2-methoxy-3-(N-methyl-N-octadecyl)carbamoyloxypropyl 2-(t,i
-dimethylpyrrolidinio-2-yl) 1-phenylethyl phosphate (20) 3-hexadecylcarbamoyloxy-2-
Methoxybutyl-erythro-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate (21) 3-heptadecylcarbamoyloxy-2-
Methoxy-1-methylpropyl・erythro-1
, 1-dimethylpiperidinio-2-ylphenylmethyl phosphate (22) 3-octadecylcarbamoyloxy 2-methoxy-2-methylpropyl erythro -1,
1-dimethylpyrrolidinio-2-ylphenylmethyl
Phosphate Note that the compound represented by the general formula (I) of the present invention includes each isomer caused by an asymmetric carbon and a mixture thereof.
本発明の一般式(I)で示される化合物は、次の方法に
より製造することができる。すなわち、数式(■):
I
■
R’ CH−0−CONR2
R8C−0R3(m)
R9CH−OH
[式中、R’ R2,R3,R) RAおよびR9は
前記と同一の意味を有する]
で表わされる化合物を、トリエチルアミンまたはキノリ
ンのような有機塩基の存在下に、塩化メチレン、塩化エ
チレン、クロロホルム、四塩化炭素、テトラヒドロフラ
ン、ベンゼン、あるいはこれらの混合物などの不活性溶
媒中でオキシ塩化リンと反応させ、次いで得られた反応
生成物を単離することなく、トリエチルアミンまたはピ
リジンのような有機塩基の存在下に
一般式(■):
HO−Q−Y −AQ (rV)[式中
、Q、YおよびAeは、前記と同一の意味を有する]
で表わされる塩と反応させる方法によって製造すること
ができる。AOで示されるアニオンの例としては、ハロ
ゲンイオン、メシルオキシイオン、トシルオキシイオン
等が挙げられる。反応温度および反応時間に特に限定は
ないが、0〜50℃の反応温度、および30分から24
時間の反応時間が好ましく利用される。The compound represented by the general formula (I) of the present invention can be produced by the following method. That is, the formula (■): I ■ R' CH-0-CONR2 R8C-0R3 (m) R9CH-OH [In the formula, R' R2, R3, R) RA and R9 have the same meanings as above] The represented compound is reacted with phosphorus oxychloride in the presence of an organic base such as triethylamine or quinoline in an inert solvent such as methylene chloride, ethylene chloride, chloroform, carbon tetrachloride, tetrahydrofuran, benzene, or mixtures thereof. and then without isolating the reaction product obtained, in the presence of an organic base such as triethylamine or pyridine, the general formula (■): HO-Q-Y-AQ (rV) [wherein Q, Y and Ae have the same meanings as above.] It can be produced by a method of reacting with a salt represented by the following. Examples of anions represented by AO include halogen ions, mesyloxy ions, tosyloxy ions, and the like. There are no particular limitations on the reaction temperature and reaction time, but the reaction temperature is 0 to 50°C, and the reaction time is 30 minutes to 24 minutes.
A reaction time of hours is preferably utilized.
出発原料の一般式(m)の化合物で、RIR7,Raお
よびR9が水素で、R2がオクタデシルで、R3がメチ
ルであるものは公知[Chem。Compounds of general formula (m) as starting materials in which RIR7, Ra and R9 are hydrogen, R2 is octadecyl, and R3 is methyl are known [Chem.
Pharm、Bull、 、32.2700−2713
(I984) 、]であるが、次のようにしても合成
することができる。その他の化合物も同様に合成するこ
とができる。Pharm, Bull, 32.2700-2713
(I984), ], but it can also be synthesized as follows. Other compounds can be similarly synthesized.
1)MeT CH2−OCONHC
16H37■
CH2−OH
次に、本発明のグリセリン誘導体(I)の血小板凝集抑
制作用の薬理実験結果を示す。1) MeT CH2-OCONHC
16H37■ CH2-OH Next, the results of pharmacological experiments on the platelet aggregation inhibiting effect of the glycerin derivative (I) of the present invention will be shown.
[血小板凝集抑制作用]
(試験方法)
雄性日本白色種家兎をベンドパルビタール麻酔し、頚動
脈より採取した血液(3,13%クエン酸Naを1/1
0容含む)より、常法に従ってPlatelet Ri
ch Plasma (P RP )および四atel
etPoor Plasma (P P P )を調製
し実験に用いた。[Platelet aggregation inhibitory effect] (Test method) Male Japanese white rabbits were anesthetized with bendoparbital, and blood was collected from the carotid artery (3.13% Na citrate was added to 1/1
(including 0 volume), Platelet Ri according to the usual method.
ch Plasma (P RP ) and 4atel
etPoor Plasma (P P P ) was prepared and used in the experiment.
なお、血小板数はPRPをPPPで希釈して約30万/
m m 3とした。The platelet count is approximately 300,000/p by diluting PRP with PPP.
It was set as m m3.
このPRP180μ党に被検薬液10μ2を加えたのち
に、PAF溶液10μ立を添加して最終濃度を1xlO
−8Mとして、血小板凝集を惹起した。After adding 10μ2 of the test drug solution to 180μ of this PRP, 10μ2 of the PAF solution was added to make a final concentration of 1xlO.
-8M induced platelet aggregation.
血小板凝集の測定は、Platelet Aggreg
ationTracer P A T −4A (二元
バイオサイエンス)を用いて行なった。Measurement of platelet aggregation is performed using Platelet Aggreg.
It was performed using ationTracer PAT-4A (Binogen Bioscience).
被検薬液及びPAF溶液の調製にはウシ血清アルブミン
を0.25%含有する生理食塩水を用いた。また、PA
Fはシグマ社(No、P−4904)を用いた。被検薬
物の凝集抑制活性は、対照PRPにおけるPAFによる
最大凝集率に対する抑制率から求めた。Physiological saline containing 0.25% bovine serum albumin was used to prepare the test drug solution and PAF solution. Also, P.A.
F was manufactured by Sigma (No. P-4904). The aggregation inhibitory activity of the test drug was determined from the inhibition rate against the maximum aggregation rate by PAF in control PRP.
(結果)
各試験薬液濃度について得られた抑制率を第1表に示す
。(Results) Table 1 shows the inhibition rates obtained for each test chemical concentration.
第1表
化合物
2x 10−6M
2x 10−’M
2x 10−’M
A 15% 72% 1
00%B 0% 79%
100%(A)2−メトキシ−3−オクタデシルカ
ルバモイルオキシプロピル・erythro −1、1
−ジメチルピロリジニオ−2−イルフェニルメチル・ホ
スフェート(後記実施例1)
(B)2−メトキシ−3−(N−メチル−Nオクタデシ
ル)カルバモイルオキシプロピル・erythro −
1、1−ジメチルピロリジニオ−2−イルフェニルメチ
ル・ホスフェート(後記実施例以上の試験結果から明ら
かなように、本発明のグリセリン誘導体はPAFの血小
板凝集作用を顕著に抑制する作用を示す。Table 1 Compound 2x 10-6M 2x 10-'M 2x 10-'M A 15% 72% 1
00%B 0% 79%
100% (A) 2-methoxy-3-octadecylcarbamoyloxypropyl・erythro-1,1
-Dimethylpyrrolidinio-2-ylphenylmethyl phosphate (Example 1 below) (B) 2-methoxy-3-(N-methyl-N-octadecyl)carbamoyloxypropyl erythro -
1,1-Dimethylpyrrolidinio-2-ylphenylmethyl phosphate (As is clear from the test results described in Examples below, the glycerin derivative of the present invention exhibits an effect of significantly suppressing the platelet aggregation effect of PAF.
本発明のグリセリン誘導体は、たとえば錠剤、顆粒剤、
散剤、カプセル剤、シロップ剤、坐剤、注射剤のような
剤形で、通常有効成分として、経口投与の場合、1回当
りO,1mg/kg 〜20mg/kgとするのが好ま
しく、また非経口投与の場合は、0.01 m87kg
〜20mg/kgとするのが好ましく、症状に応じて
1〜4回投与するのが好都合である。なお、投与量は対
象患者の状態、投与方法に応じて適宜増減される。上記
の各種製剤は通常用いられる担体もしくは賦形剤を含む
ものである。The glycerin derivative of the present invention can be used, for example, in tablets, granules,
When administered orally in dosage forms such as powders, capsules, syrups, suppositories, and injections, the active ingredient is preferably O, 1 mg/kg to 20 mg/kg per dose; For oral administration, 0.01 m87kg
The dose is preferably ~20 mg/kg, and conveniently administered 1 to 4 times depending on the symptoms. Note that the dosage is adjusted as appropriate depending on the condition of the target patient and the administration method. The various formulations mentioned above contain commonly used carriers or excipients.
次に、本発明のグリセリン誘導体の製造法および調剤例
を実施例により説明する。なお、ホスフェートとして示
された化合物は分子内塩の形態にある。参考例は、本発
明のグリセリン誘導体の製造に利用される原料の製造例
を示す。Next, the manufacturing method and preparation example of the glycerin derivative of the present invention will be explained with reference to Examples. In addition, the compound shown as a phosphate is in the form of an inner salt. The reference example shows a production example of raw materials used for production of the glycerin derivative of the present invention.
[参考例1]
2−メトキシ−1−オクタデシルカルバモイルオキシ−
3−トリフェニルメトキシプロパン(A化合物)、及び
2−メトキシ−1−(N−メチル−N−オクタデシルカ
ルバモイルオキシ)−3−トリフェニル・メトキシプロ
パン B ム
1−オクタデシルカルバモイルオキシ−3−トリフェニ
ルメトキシ−2−プロパツール3.8gを、ジメチルス
ルホキシド56.2mILとテトラヒドロフラン33.
8mJZとの混合溶媒に溶解し、ヨウ化メチル0.38
ml1、粉末水酸化カリウム0.49gを加え、5℃以
下で1時間攪拌した。反応液を氷水100rnJZに注
ぎ込み、酢酸エチル(30mfiX3)にて抽出し、抽
出液を水、飽和食塩水の順に洗浄し、無水硫酸ナトリウ
ムで乾燥した。溶媒を留去して得られた残漬を、高速液
体クロマトグラフィー(シリカゲル、溶媒;ヘキサン:
酢酸エチル=4:1)にて分取精製し、標題のA化合物
0.8g及び標題のB化合物0.8gを得た。(Rr値
:A化合物くB化合物、シリカゲル薄層クロマトグラフ
ィー、溶媒;ヘキサン:酢酸エチル=2:1)
■±立士
’HNMR(CDCfi3 ) δ :0. 7〜1
.0 (m、3H)
1、 25 (s、30H)1.3〜1.
6 (m、 2H)。[Reference Example 1] 2-Methoxy-1-octadecylcarbamoyloxy-
3-triphenylmethoxypropane (compound A), and 2-methoxy-1-(N-methyl-N-octadecylcarbamoyloxy)-3-triphenyl methoxypropane B 1-octadecylcarbamoyloxy-3-triphenylmethoxy -2-Propatool 3.8g, dimethyl sulfoxide 56.2mL and tetrahydrofuran 33.
Dissolved in a mixed solvent with 8mJZ, methyl iodide 0.38
ml1 and 0.49 g of powdered potassium hydroxide were added, and the mixture was stirred at 5° C. or lower for 1 hour. The reaction solution was poured into 100rnJZ of ice water and extracted with ethyl acetate (30mfiX3). The extract was washed with water and saturated brine in that order, and dried over anhydrous sodium sulfate. The residue obtained by distilling off the solvent was subjected to high performance liquid chromatography (silica gel, solvent; hexane:
The mixture was fractionated and purified using ethyl acetate (4:1) to obtain 0.8 g of the title compound A and 0.8 g of the title compound B. (Rr value: Compound A vs. Compound B, silica gel thin layer chromatography, solvent: hexane: ethyl acetate = 2:1) ■±Tachi'HNMR (CDCfi3) δ: 0. 7-1
.. 0 (m, 3H) 1, 25 (s, 30H) 1.3-1.
6 (m, 2H).
2.8〜3.7 (m、5H)。2.8-3.7 (m, 5H).
3.39 (s、3H)。3.39 (s, 3H).
3.9〜4.7 (m、3H)。3.9-4.7 (m, 3H).
6.9〜7. 6 (m、 5H)IR(neat
) Cm−’:
3500〜3100. 3050. 2920゜285
0、 1710. 1500. 1480゜1440、
1240. 1140. 1080゜旦」−1物
’HNMR(CDCj23 ) δ :0、 7〜1
. 0 (m、3H)
1、 25 (S、 30H)1、 3〜
1. 6 (m、 2H)。6.9-7. 6 (m, 5H)IR(neat
) Cm-': 3500-3100. 3050. 2920°285
0, 1710. 1500. 1480°1440,
1240. 1140. 1080°-1 substance HNMR (CDCj23) δ: 0, 7-1
.. 0 (m, 3H) 1, 25 (S, 30H) 1, 3~
1. 6 (m, 2H).
2、 5〜3. 6 (m、8H)。2, 5-3. 6 (m, 8H).
3.42 (s、 3H)。3.42 (s, 3H).
3.9〜4.4 (m、 2H)。3.9-4.4 (m, 2H).
6、 9〜7. 6 (m、 5H)IR(nea
t) Cm−’:
2920、 2850. 1700. 1440゜14
00、 1180. 1080゜
[参考例2]
(i)2−メトキシ−3−オクタデシルカルバモイルオ
キシ−1−プロパツール
参考例1のようにして得られたA化合物1.2gをクロ
ロホルム77mILに溶かし、炭酸カルシウム155m
gの存在下、10%パラジウム−炭素155mgを用い
て接触還元を行なった。室温で2日間反応を行なった後
、不溶物を濾別し、濾液を減圧濃縮して得られた残渣を
シリカゲルカラムクロマトグラフィー(溶媒:クロロホ
ルム:メタノール=100:1)で絹製して標題化合物
0.48gを得た。6, 9-7. 6 (m, 5H)IR(nea
t) Cm-': 2920, 2850. 1700. 1440°14
00, 1180. 1080° [Reference Example 2] (i) 2-Methoxy-3-octadecylcarbamoyloxy-1-propanol 1.2 g of Compound A obtained as in Reference Example 1 was dissolved in 77 ml of chloroform, and 155 ml of calcium carbonate was dissolved.
Catalytic reduction was carried out using 155 mg of 10% palladium-carbon in the presence of g. After reacting for 2 days at room temperature, insoluble materials were filtered off, and the filtrate was concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (solvent: chloroform:methanol = 100:1) to obtain the title compound. 0.48g was obtained.
’HNMR(CDCU3)δ: 0.7〜1.0 (m、3H) 1.26 (s、30H) 1.3〜1.6 (m、2H)。'HNMR (CDCU3) δ: 0.7-1.0 (m, 3H) 1.26 (s, 30H) 1.3-1.6 (m, 2H).
2、 4〜2. 7 (m、 IH)。2, 4-2. 7 (m, IH).
2、 9〜3. 8 (m、 5H)。2, 9-3. 8 (m, 5H).
3、 46 (s、 3H)。3, 46 (s, 3H).
4、 0〜4. 3 (m、 2H)。4, 0-4. 3 (m, 2H).
4、 6〜5. 0 (br、 IH)(ii)
2−メトキシ−3−(N−メチル−N−オクタデシル)
カルバモイルオキシ−1−プロパツール
(i)におけると同様にして、参考例1のようにして得
られたB化合物1.4gを接触還元して、標題化合物0
.62gを得た。4, 6-5. 0 (br, IH) (ii)
2-Methoxy-3-(N-methyl-N-octadecyl)
In the same manner as in carbamoyloxy-1-propatol (i), 1.4 g of Compound B obtained as in Reference Example 1 was catalytically reduced to give the title compound 0.
.. 62g was obtained.
’HNMR(CDCJZ3 )δ: 0.7〜1.0 (m、3H) 1.26 (s、30H) 1.0〜1.8 (m、2H)。'HNMR (CDCJZ3) δ: 0.7-1.0 (m, 3H) 1.26 (s, 30H) 1.0-1.8 (m, 2H).
2.4〜2.6 (m、IH)。2.4-2.6 (m, IH).
2.89 (s、3H)。2.89 (s, 3H).
3.0〜3.8 (m、5H)。3.0-3.8 (m, 5H).
3.47 (s、3H)。3.47 (s, 3H).
4.2 (d、2H)。4.2 (d, 2H).
IR(にBr)cm−’:
2900、 2850. 1700. 1440゜14
00、 1180. 1080
[参考例3]
erythro −1、1−ジメチ7L/−2−(a−
ヒドロキシベンジル)ピロリジニウム・p−トルエンス
ルホネート
erythro −1−メチル−2−(α−ヒドロキシ
ベンジル)ピロリジン2.16gをアセトン20m2に
溶解し、これにP−トルエンスルホン酸メチル2.10
gを滴下した。室温で攪拌し、更に加熱還流して冷却し
た後、析出した結晶を濾過乾燥し、目的物3.80gを
得た。mp:155〜157℃
IHNMR(DMSO−d6’)δ:
1.5〜2.2 (m、4H)。IR (Br) cm-': 2900, 2850. 1700. 1440°14
00, 1180. 1080 [Reference Example 3] erythro-1,1-dimethy7L/-2-(a-
2.16 g of erythro-1-methyl-2-(α-hydroxybenzyl)pyrrolidine is dissolved in 20 m2 of acetone, and 2.10 g of methyl p-toluenesulfonate is dissolved in 20 m2 of acetone.
g was added dropwise. After stirring at room temperature and further heating to reflux and cooling, the precipitated crystals were filtered and dried to obtain 3.80 g of the desired product. mp: 155-157°C IHNMR (DMSO-d6') δ: 1.5-2.2 (m, 4H).
2.28 (S、3H)。2.28 (S, 3H).
3.12 (s、3H)。3.12 (s, 3H).
3.20 (s、3H)。3.20 (s, 3H).
3.3〜3.85 (m、3H)。3.3-3.85 (m, 3H).
5、 2〜5. 35 (m、 IH)。5, 2-5. 35 (m, IH).
6. 09 (d、 IH)。6. 09 (d, IH).
6.9〜7. 5 (m、9H)
IR(KBr)cm−’:
3320.3070,3025,3000゜2975、
2920. 1450. 1215゜1190、 1
135. 1110. 1045゜1030、 101
0. 820. 700゜690、 570
[実施例1]
2−メトキシ−3−オクタデシルカルバモイルオキシプ
ロビル・erythro −1、1−ジメチルピロリジ
ニオ−2−イルフェニルメチル・ホスフェート
窒素雰囲気下、オキシ塩化リン0.14mILとトリエ
チルアミン0.40m1をアルミナを通したクロロホル
ム3.5mJ!に溶解し、しばらく室温で攪拌した。こ
れに水冷下に、参考例2(i)で得た2−メトキシ−3
−オクタデシルカルバモイルオキシ−1−プロパツール
466mgのクロロホルム(前述に同じ)3.5mJZ
溶液を滴下した。滴下後、30分間室温にて攪拌し、こ
れに参考例3で得た四級塩657mg及び乾燥ピリジン
12ml1.溶液を加えた。室温で一夜攪拌後、重曹6
50mgとJgl、5mlを加えてしばらく攪拌後、減
圧下にて溶媒を留去した。次に、トルエン−塩化メチレ
ン混合溶媒(v/v= 1 / 1 ) 15mlを加
え、不溶物を濾別し、母液を減圧上濃縮して得られた残
渣をテトラヒドロフラン−水混合溶媒(v / v −
9575)に溶解し、アンバーライトMB−3のイオン
交換樹脂カラムに通した。6.9-7. 5 (m, 9H) IR (KBr) cm-': 3320.3070,3025,3000°2975,
2920. 1450. 1215°1190, 1
135. 1110. 1045°1030, 101
0. 820. 700゜690, 570 [Example 1] 2-Methoxy-3-octadecylcarbamoyloxyprobyl erythro-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate Under nitrogen atmosphere, 0.14 ml of phosphorous oxychloride And 3.5mJ of chloroform made by passing 0.40ml of triethylamine through alumina! and stirred for a while at room temperature. To this was added 2-methoxy-3 obtained in Reference Example 2(i) under water cooling.
- Octadecylcarbamoyloxy-1-propatol 466 mg of chloroform (same as above) 3.5 mJZ
The solution was added dropwise. After dropping, the mixture was stirred at room temperature for 30 minutes, and 657 mg of the quaternary salt obtained in Reference Example 3 and 12 ml of dry pyridine were added thereto. solution was added. After stirring overnight at room temperature, 6% baking soda
After adding 50 mg and 5 ml of Jgl and stirring for a while, the solvent was distilled off under reduced pressure. Next, 15 ml of a toluene-methylene chloride mixed solvent (v/v=1/1) was added, insoluble matter was filtered off, and the mother liquor was concentrated under reduced pressure. The resulting residue was added to a tetrahydrofuran-water mixed solvent (v/v −
9575) and passed through an ion exchange resin column of Amberlite MB-3.
テトラヒドロフラン−水混合溶媒(前述に同じ)で溶出
し、減圧上溶媒を留去して得られた残渣をシリカゲルカ
ラムクロマトグラフィー(クロロホルム:メタノール:
水=80 : 20 : 2)にて錆製して目的物18
1mgを得た。Elution was performed with a tetrahydrofuran-water mixed solvent (same as above), and the solvent was distilled off under reduced pressure. The resulting residue was subjected to silica gel column chromatography (chloroform:methanol:
Rust made with water = 80:20:2) and object 18
1 mg was obtained.
IHNMR(CD30D)δ: 0.7〜1.0 (m、3H)。IHNMR (CD30D) δ: 0.7-1.0 (m, 3H).
1.28 (s、30H)。1.28 (s, 30H).
1.3〜1.7 (m、2H)。1.3-1.7 (m, 2H).
1、 8〜2. 7 (m、 4)()2、 8〜
3. 9 (m、 19H)。1, 8-2. 7 (m, 4) ()2, 8~
3. 9 (m, 19H).
5、 7 (d、 IH)。5, 7 (d, IH).
7、 2〜7. 6 (m、 5H)I R(K
Br)cm−’:
3650〜3100. 2900. 2850゜171
0、 1460. 1240. 1060゜[実施例2
]
2−メトキシ−3−(N−メチル−N−オクタデシル)
カルバモイルオキシプロピル・erythr。7, 2-7. 6 (m, 5H) I R (K
Br) cm-': 3650-3100. 2900. 2850°171
0, 1460. 1240. 1060° [Example 2
] 2-methoxy-3-(N-methyl-N-octadecyl)
Carbamoyloxypropyl erythr.
−1,1−ジメチルピロリジニオ−2−イルフェニルメ
チル・ホスフェート
参考例2(ii)で得た2−メトキシ−3−(N−メチ
ル−N−オクタデシル)カルバモイルオキシ−1−プロ
パツール482mg、参考例3で得た四級塩657mg
、オキシ塩化リン0.14ml1.、トリエチルアミン
0.4m1l、アルミナカラム処理のクロロホルム7m
l、乾燥ピリジン12ml1より、実施例1と同様にし
て、目的物201mgを得た。-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate 482 mg of 2-methoxy-3-(N-methyl-N-octadecyl)carbamoyloxy-1-propatol obtained in Reference Example 2(ii), 657 mg of quaternary salt obtained in Reference Example 3
, 0.14 ml of phosphorus oxychloride1. , 0.4 ml of triethylamine, 7 ml of chloroform treated with alumina column.
In the same manner as in Example 1, 201 mg of the target product was obtained from 12 ml of dry pyridine.
’HNMR(CD30D) δ : 0、 7〜1. 0 (m、 3H)。'HNMR (CD30D) δ: 0, 7-1. 0 (m, 3H).
1、 28 (s、 30H)。1, 28 (s, 30H).
1、 3〜1. 7 (m、 2H)。1, 3-1. 7 (m, 2H).
1、 8〜2. 4 (m、 4H)2、 85
(s、 3H)2、 9〜4. 0 (
m、 19H)。1, 8-2. 4 (m, 4H)2, 85
(s, 3H) 2, 9-4. 0 (
m, 19H).
5、 7 (d、 IH)。5, 7 (d, IH).
7.2〜7.6 (m、 5H)
I R(KBr)cm−’:
3650〜3100. 2900. 2B30゜169
0、 1450. 1230. 1070゜[製剤実施
例1]錠剤
(I)2−メトキシ−3−オクタデシルカルバモイルオ
キシプロビル・erythro −1、1−ジメチルピ
ロリジニオ−2−イルフェニルメチル・ホスフェート
50.0g(2)乳糖
110.0g(3)結晶セルロース
80.0g(4)トウモロコシ澱粉 30.0
g(5)カルボキシメチル
セルロースカルシウム 20.0g
(6)ヒドロキシプロピル
セルロース 8.0g
(7)ステアリン酸マグネシウム 2.0g1000錠
300g
上記(I)〜(6)の各成分を常法により顆粒化した後
、(7)を加え混合し一錠(300mg)中(I)を5
0mg含有する錠剤を得た。7.2-7.6 (m, 5H) IR(KBr)cm-': 3650-3100. 2900. 2B30°169
0, 1450. 1230. 1070° [Formulation Example 1] Tablet (I) 2-methoxy-3-octadecylcarbamoyloxyprobil erythro-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate
50.0g (2) Lactose
110.0g (3) Crystalline cellulose
80.0g (4) Corn starch 30.0
g (5) Carboxymethyl cellulose calcium 20.0 g (6) Hydroxypropyl cellulose 8.0 g (7) Magnesium stearate 2.0 g 1000 tablets 300 g After granulating each of the components (I) to (6) above by a conventional method, Add (7) and mix, containing 5 of (I) in one tablet (300 mg).
Tablets containing 0 mg were obtained.
[製剤実施例2]注射剤
2−メトキシ−3−オクタデシルカルバモイルオキシプ
ロピル・erythro −1、1−ジメチルピロリジ
ニオ−2−イルフェニルメチル・ホスフェート2g、お
よびマンニット100gを計量し、注射用蒸留水にて1
2に溶解し、無菌ろ過後、5mB、バイアル瓶に0.5
mlずつ分注し、常法により凍結乾燥を行ない、乾燥後
密栓し、注射剤用凍結乾燥製剤を得た。[Formulation Example 2] Injection 2-methoxy-3-octadecylcarbamoyloxypropyl erythro-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate 2 g and mannitol 100 g were weighed and distilled for injection. In water 1
2 and after sterile filtration, 5 mB, 0.5 mB in a vial.
The mixture was dispensed in ml portions, freeze-dried using a conventional method, and sealed tightly after drying to obtain a freeze-dried preparation for injection.
[製剤実施例3]軟カプセル剤
(I)2−メトキシ−3−オクタデシルカルバモイルオ
キシプロピル・eryLhro −1、1−ジメチルピ
ロリジニオ−2−イルフェニルメチル・ホスフェート
10.0g(2)ポリエチレン
グリコール
400 160.0g
(3)ポリビニルピロリドン 5.0g(4)グリ
セリン 75.0g1000力プセル25
0g
上記(I)〜(4)の各成分を均一に溶解し、内容液と
したのち、常法によりゼラチンシートで被包し、1カプ
セル中(I)を10mg含有する軟カプセル剤を得た。[Formulation Example 3] Soft capsule (I) 2-methoxy-3-octadecylcarbamoyloxypropyl eryLhro-1,1-dimethylpyrrolidinio-2-ylphenylmethyl phosphate
10.0g (2) Polyethylene glycol 400 160.0g (3) Polyvinylpyrrolidone 5.0g (4) Glycerin 75.0g 1000 force Pcel 25
0g Each of the above components (I) to (4) was uniformly dissolved to form a liquid content, which was then encapsulated with a gelatin sheet by a conventional method to obtain a soft capsule containing 10mg of (I) per capsule. .
特許出願人 日本ケミファ株式会社 代 理 人 弁理士 柳川泰男Patent applicant: Nippon Chemifa Co., Ltd. Representative Patent Attorney Yasuo Yanagawa
Claims (1)
しくは分枝鎖アルキル基を示し、R^2は、炭素数10
〜22の直鎖または分枝鎖アルキル基を示し、R^3は
、炭素数1〜10の直鎖または分枝鎖アルキル基、置換
基を有してもよいアラルキル基(アルキレン基の炭素数
は1〜3)を示し、Qは、式(II) ▲数式、化学式、表等があります▼(II) (但し、R^4は、炭素数1〜6のアルキル基、または
低級アルキル基で置換されていてもよいアリール基を示
し、mおよびnは、それぞれ0〜2の整数であり、かつ
、m+n=0〜2を満足する数である)で表わされる基
を示し、Yは ▲数式、化学式、表等があります▼(R^5とR^6と
は、それぞれ独立に炭素数1〜6の直鎖または分枝鎖ア
ルキル基を示す)を環形成基として含む含窒素複素環基
を示し(ただし、含窒素複素環基と隣接する基Qとは該
環の炭素原子を介して結合している)、そしてR^7、
R^8およびR^9は、それぞれ独立に水素、炭素数1
〜6の直鎖または分枝鎖アルキル基、アリール基もしく
はアラルキル基を示す] で表わされるグリセリン誘導体。 2、一般式(III): ▲数式、化学式、表等があります▼(III) [式中、R^1は、水素、または炭素数1〜4の直鎖も
しくは分枝鎖アルキル基を示し、R^2は、炭素数10
〜22の直鎖または分枝鎖アルキル基を示し、R^3は
、炭素数1〜10の直鎖または分枝鎖アルキル基、置換
基を有してもよいアラルキル基(アルキレン基の炭素数
は1〜3)を示し、R^7、R^8およびR^9は、そ
れぞれ独立に水素、炭素数1〜6の直鎖または分枝鎖ア
ルキル基、アリール基もしくはアラルキル基を示す] で表わされる化合物を、塩基の存在下に、オキシ塩化リ
ンおよび一般式(IV): HO−Q−Y・A^■(IV) [式中、Qは、式(II) ▲数式、化学式、表等があります▼(II) (但し、R^4は、炭素数1〜6のアルキル基、または
低級アルキル基で置換されていてもよいアリール基を示
し、mおよびnは、それぞれ0〜2の整数であり、かつ
、m+n=0〜2を満足する数である)で表わされる基
を示し、Yは ▲数式、化学式、表等があります▼(R^5とR^6と
は、それぞれ独立に炭素数1〜6の直鎖または分枝鎖ア
ルキル基を示す)を環形成基として含む含窒素複素環基
を示し(ただし、含窒素複素環基と隣接する基Qとは該
環の炭素原子を介して結合している)、A^■はアニオ
ンを示す] で表わされる塩と反応させることを特徴とする、一般式
( I ): ▲数式、化学式、表等があります▼( I ) [式中、R^1、R^2、R^3、R^7、R^8、R
^9、QおよびYは、上記と同じ意味を有する] で表わされるグリセリン誘導体の製造方法。 3、一般式( I ): ▲数式、化学式、表等があります▼( I ) [式中、R^1は、水素、または炭素数1〜4の直鎖も
しくは分枝鎖アルキル基を示し、R^2は、炭素数10
〜22の直鎖または分枝鎖アルキル基を示し、R^3は
、炭素数1〜10の直鎖または分枝鎖アルキル基、置換
基を有してもよいアラルキル基(アルキレン基の炭素数
は1〜3)を示し、Qは、式(II) ▲数式、化学式、表等があります▼(II) (但し、R^4は、炭素数1〜6のアルキル基、または
低級アルキル基で置換されていてもよいアリール基を示
し、mおよびnは、それぞれ0〜2の整数であり、かつ
、m+n=0〜2を満足する数である)で表わされる基
を示し、Yは ▲数式、化学式、表等があります▼(R^5とR^6と
は、それぞれ独立に炭素数1〜6の直鎖または分枝鎖ア
ルキル基を示す)を環形成基として含む含窒素複素環基
を示し(ただし、含窒素複素環基と隣接する基Qとは該
環の炭素原子を介して結合している)、そしてR^7、
R^8およびR^9は、それぞれ独立に水素、炭素数1
〜6の直鎖または分枝鎖アルキル基、アリール基もしく
はアラルキル基を示す] で表わされるグリセリン誘導体を含有する医薬組成物。[Claims] 1. General formula (I): ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) [In the formula, R^1 is hydrogen, or a linear or branched chain having 1 to 4 carbon atoms. Represents a chain alkyl group, R^2 has 10 carbon atoms
-22 linear or branched alkyl group, R^3 is a linear or branched alkyl group having 1 to 10 carbon atoms, an aralkyl group that may have a substituent (the number of carbon atoms in the alkylene group is 1 to 3), and Q is the formula (II) ▲Mathematical formula, chemical formula, table, etc.▼(II) (However, R^4 is an alkyl group having 1 to 6 carbon atoms or a lower alkyl group. represents an optionally substituted aryl group, m and n are each an integer of 0 to 2, and a number satisfying m+n=0 to 2), and Y represents the formula ▲ , chemical formulas, tables, etc. ▼ (R^5 and R^6 each independently represent a straight or branched alkyl group having 1 to 6 carbon atoms) as a ring-forming group. (However, the nitrogen-containing heterocyclic group and the adjacent group Q are bonded via the carbon atom of the ring), and R^7,
R^8 and R^9 are each independently hydrogen, carbon number 1
-6 linear or branched alkyl group, aryl group or aralkyl group] A glycerin derivative represented by: 2. General formula (III): ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (III) [In the formula, R^1 represents hydrogen or a straight or branched alkyl group having 1 to 4 carbon atoms, R^2 is carbon number 10
-22 linear or branched alkyl group, R^3 is a linear or branched alkyl group having 1 to 10 carbon atoms, an aralkyl group that may have a substituent (the number of carbon atoms in the alkylene group is represents 1 to 3), and R^7, R^8 and R^9 each independently represent hydrogen, a straight or branched alkyl group having 1 to 6 carbon atoms, an aryl group or an aralkyl group] The represented compound is mixed with phosphorus oxychloride and general formula (IV) in the presence of a base: HO-Q-Y・A^■(IV) [wherein, Q is formula (II)] ▲Mathematical formula, chemical formula, table etc.▼(II) (However, R^4 represents an alkyl group having 1 to 6 carbon atoms or an aryl group which may be substituted with a lower alkyl group, and m and n each represent an alkyl group having 1 to 6 carbon atoms. is an integer and satisfies m+n=0 to 2), and Y is a ▲numeric formula, chemical formula, table, etc.▼(R^5 and R^6 are each independent represents a straight-chain or branched alkyl group having 1 to 6 carbon atoms) as a ring-forming group (however, the group Q adjacent to the nitrogen-containing heterocyclic group refers to the carbon atoms of the ring). A general formula (I) characterized by reacting with a salt represented by (bonded through an atom), A^■ indicates an anion]: ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (I) [In the formula, R^1, R^2, R^3, R^7, R^8, R
^9, Q and Y have the same meanings as above] A method for producing a glycerin derivative represented by: 3. General formula (I): ▲Mathematical formula, chemical formula, table, etc.▼(I) [In the formula, R^1 represents hydrogen or a straight or branched alkyl group having 1 to 4 carbon atoms, R^2 is carbon number 10
-22 linear or branched alkyl group, R^3 is a linear or branched alkyl group having 1 to 10 carbon atoms, an aralkyl group that may have a substituent (the number of carbon atoms in the alkylene group is 1 to 3), and Q is the formula (II) ▲Mathematical formula, chemical formula, table, etc.▼(II) (However, R^4 is an alkyl group having 1 to 6 carbon atoms or a lower alkyl group. It represents an optionally substituted aryl group, m and n are each an integer of 0 to 2, and a number satisfying m+n=0 to 2), and Y represents the formula ▲ , chemical formulas, tables, etc. ▼ (R^5 and R^6 each independently represent a straight or branched alkyl group having 1 to 6 carbon atoms) as a ring-forming group. (However, the nitrogen-containing heterocyclic group and the adjacent group Q are bonded via the carbon atom of the ring), and R^7,
R^8 and R^9 are each independently hydrogen, carbon number 1
-6 linear or branched alkyl group, aryl group or aralkyl group] A pharmaceutical composition containing a glycerin derivative represented by the following.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63291474A JP2534902B2 (en) | 1988-11-18 | 1988-11-18 | Novel glycerin derivative and platelet aggregation inhibitor containing the derivative |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63291474A JP2534902B2 (en) | 1988-11-18 | 1988-11-18 | Novel glycerin derivative and platelet aggregation inhibitor containing the derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH02138189A true JPH02138189A (en) | 1990-05-28 |
JP2534902B2 JP2534902B2 (en) | 1996-09-18 |
Family
ID=17769342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63291474A Expired - Lifetime JP2534902B2 (en) | 1988-11-18 | 1988-11-18 | Novel glycerin derivative and platelet aggregation inhibitor containing the derivative |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2534902B2 (en) |
-
1988
- 1988-11-18 JP JP63291474A patent/JP2534902B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP2534902B2 (en) | 1996-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4657911A (en) | 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function | |
JP4171702B2 (en) | Novel α-amino-N- (diaminophosphinyl) lactam derivative | |
EP1423115B1 (en) | Antiangiogenic activity of nitrogen substituted thalidomide analogs | |
EP0043123A1 (en) | Novel substituted pyrazinyl-1,2,4-oxadiazol-5-ones, a process for preparing same and a pharmaceutical composition containing same | |
JPH11504947A (en) | N-Aminoalkyldibenzofurancarboxamides as dopamine receptor subtype specific ligands | |
US5763454A (en) | Crystal form of anhydrous 7-( 1α,5α,6α!-6-amino-3-azabicyclo 3.1.0!hex-3-yl)-6-fluoro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1,8 naphthyridine-3-carboxylic acid, methanessulfonic acid salt | |
JP2022547617A (en) | IL-17A modulators and uses thereof | |
KR20070115258A (en) | 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoline besylate salt, preparation and therapeutic use thereof | |
US4507294A (en) | Imidazo[1,2-a]pyrazines | |
US4483861A (en) | Antihypertensive sulfur-containing compounds | |
JP2534894B2 (en) | Novel glycerin derivative and antihypertensive agent containing the derivative | |
JPS60202870A (en) | Acylaminooxo or hydroxy substituted alkylaminothiazines andthiazepines | |
CN102276595A (en) | Oxazolidinone antibiotic containing five-membered heterocycles | |
JPH02138189A (en) | Novel glycerin derivative, production thereof and drug composition containing same derivative | |
WO2002094829A1 (en) | Carbapenem compound | |
JPS63208520A (en) | Blood platelet agglutination inhibitor containing pyrazine derivative | |
JPH01104064A (en) | Basically substituted benzofurancarboxylic acid amide, manufacture and medicine | |
JPH0192A (en) | Novel glycerin derivative and antihypertensive agent | |
JP2534893B2 (en) | Novel glycerin derivative and platelet aggregation inhibitor containing the derivative | |
JP2512306B2 (en) | Novel glycerin derivative and platelet aggregation inhibitor | |
US3784545A (en) | 1-(5-phenyl-4-oxo-2-oxazolin-2-yl)-4-cinnamoylpiperazines | |
JP2512307B2 (en) | Novel glycerin derivative and platelet aggregation inhibitor | |
JPH04117382A (en) | 1-methylcarbapenem derivative and preparation thereof | |
JP2512304B2 (en) | Novel glycerin derivative and antihypertensive agent | |
JPS6248673B2 (en) |